Investor Relations

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Latest Investor Presentation Latest Earnings Presentation
(Updated September 9, 2021) (Updated August 5, 2021)
Stock Information
Recent News
Sep 17, 2021

The U.S. Centers for Disease Control and Prevention (CDC) recently provided updated guidance stating that participants in the Novavax PREVENT-19 Phase 3 clinical trial meet the criteria to be...

Sep 16, 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation in a...

Sep 10, 2021

Takeda Pharmaceutical Company Limited announced on September 7, 2021 that it had finalized an agreement with the government of Japan’s Ministry of Health, Labour and Welfare (MHLW) for the...

View All Press Releases

Monday, September 13, 2021 - Wednesday, September 15, 2021
7:00am - 1:00pm EDT

Date: Monday, September 13, 2021 Time: Available on-demand starting at 7:00 a.m. Eastern Time (ET) Moderator: Vernon Bernardino Novavax participants: Gregory M. Glenn, M.D., President, Research...

Friday, September 10, 2021
2:00pm - 2:30pm EDT

Fireside Chat Date: Friday, September 10, 2021 Time: 2:00 – 2:30 p.m. Eastern Time (ET) Moderator: Jeffrey Hung Novavax participants: Gregory M. Glenn, M.D., President, Research and Development...

Thursday, September 9, 2021
4:10pm - 4:55pm EDT

View All Events